On the recordJuly 26, 2022
Mr. President, I rise today to address my colleagues on the topic of competition policy, just as I did last week, and I will continue to do until we take action. Now, I want to start out speaking briefly about one part of competition policy that is very important, and that has to do with prescription drugs. As we all know, brand-name prescription drugs in the U.S. are more than 250 percent of those in other industrialized countries. In many cases, Americans pay the highest prices in the world for these drugs. Yet it is our country, our taxpayers, that have put in the money for the research. The high price of prescription drugs has put treatments out of reach for many Americans, even those with insurance, and driven up the tab for taxpayers. Examples: One of my constituents, Ramae, from Bemidji, was diagnosed in 2018 with an incurable blood cancer, multiple myeloma. She relies on a drug called Revlimid that costs about 15,000 a year. Ramae depleted her life savings, cashed out her 401(k), and sold her house in order to afford this drug she needs to survive. Actually, nearly 20 percent of older adults have reported not taking their medicines as prescribed because of the cost. The good news--and this gets to competition. Years and years ago, as you know, Mr. President, the pharmaceutical industry installed in law a provision that said Medicare was banned from negotiating less expensive prices for drugs--banned from negotiating.…





